Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 8/20 | 1.00 |
| ▸ | SHBG | P04278 | 7/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 1.00 |
| ▸ | SERPINA6 | P08185 | 6/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 5/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 6/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.78 |
| ▸ | MAPT | P10636 | 3/20 | 0.78 |
| ▸ | MEN1 | O00255 | 2/20 | 0.78 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.78 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.78 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cortodoxone SCHEMBL16834876 | 1.00 | HSD17B10 (1.00) | HSD17B10SHBGSMN1; SMN2SERPINA6CYP2C19 | |
| Cortodoxone SCHEMBL3641463 | 1.00 | HSD17B10 (1.00) | HSD17B10SHBGSMN1; SMN2SERPINA6CYP2C19 | |
| Cortodoxone SCHEMBL13352414 | 1.00 | HSD17B10 (1.00) | HSD17B10SHBGSMN1; SMN2SERPINA6CYP2C19 | |
| Cortodoxone SCHEMBL42590 | 1.00 | HSD17B10 (1.00) | HSD17B10SHBGSMN1; SMN2SERPINA6CYP2C19 | |
| Cortodoxone SCHEMBL1592718 | 1.00 | HSD17B10 (1.00) | HSD17B10SHBGSMN1; SMN2SERPINA6CYP2C19 | |
| Cortodoxone SCHEMBL24900239 | 1.00 | HSD17B10 (1.00) | HSD17B10SHBGSMN1; SMN2SERPINA6CYP2C19 | |
| Cortodoxone SCHEMBL14360590 | 1.00 | HSD17B10 (1.00) | HSD17B10SHBGSMN1; SMN2SERPINA6CYP2C19 | |
| Cortodoxone SCHEMBL17906542 | 1.00 | HSD17B10 (1.00) | HSD17B10SHBGSMN1; SMN2SERPINA6CYP2C19 | |
| Cortodoxone SCHEMBL13768127 | 1.00 | HSD17B10 (1.00) | HSD17B10SHBGSMN1; SMN2SERPINA6CYP2C19 | |
| SCHEMBL6019058 | 0.91 | HSD17B10 (0.84) | HSD17B10SHBGSMN1; SMN2SERPINA6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11938141-B2 | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives | CASSIOPEA S.P.A. (IT) | 2024-03-26 | — | — | US | disclosed |
| US-20230104965-A1 | ENZYMATIC PROCESS FOR OBTAINING 17 ALPHA-MONOESTERS OF CORTEXOLONE AND/OR ITS 9,11-DEHYDRODERIVATIVES | CASSIOPEA S.P.A. (IT) | 2023-04-06 | — | — | US | disclosed |
| US-11207332-B2 | Enzymatic process for obtaining 17 α-monoesters of cortexolone and/or its 9,11-dehydroderivatives | CASSIOPEA S.P.A. (IT) | 2021-12-28 | — | — | US | disclosed |
| US-10716796-B2 | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives | CASSIOPEA S.P.A. (IT) | 2020-07-21 | — | — | US | disclosed |
| US-20200155572-A1 | ENZYMATIC PROCESS FOR OBTAINING 17 ALPHA-MONOESTERS OF CORTEXOLONE AND/OR ITS 9,11-DEHYDRODERIVATIVES | CASSIOPEA S.P.A. (IT) | 2020-05-21 | — | — | US | disclosed |
| EP-3521298-A1 | CORTEXOLONE-17-ALPHA-PROPIONATE CRYSTALLINE FORM III AND ITS PHARMACEUTICAL USE | Cassiopea S.p.A. (IT) | 2019-08-07 | — | — | EP | disclosed |
| EP-2966175-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING CORTEXOLONE-17-ALPHA-PROPIONATE | CASSIOPEA S P A (IT) | 2019-05-08 | — | — | EP | disclosed |
| US-20190083511-A1 | ENZYMATIC PROCESS FOR OBTAINING 17 ALPHA-MONOESTERS OF CORTEXOLONE AND/OR ITS 9,11-DEHYDRODERIVATIVES | CASSIOPEA S.P.A. (IT) | 2019-03-21 | — | — | US | disclosed |
| US-10166245-B2 | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives | CASSIOPEA S.P.A. (IT) | 2019-01-01 | — | — | US | disclosed |
| US-10159682-B2 | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives | CASSIOPEA S.P.A. (IT) | 2018-12-25 | — | — | US | disclosed |
| US-20160051566-A1 | Enzymatic Process for Obtaining 17 Alpha-Monoesters of Cortexolone and/or Its 9,11-Dehydroderivatives | CASSIOPEA S.P.A. (IT) | 2016-02-25 | — | — | US | disclosed |
| EP-2966175-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING CORTEXOLONE-17-ALPHA-PROPIONATE | Cassiopea S.p.A. (IT) | 2016-01-13 | — | — | EP | disclosed |
| EP-2503004-B1 | Cortexolone-17alpha-propionate in crystalline form I | CASSIOPEA S P A (IT) | 2015-09-02 | — | — | EP | disclosed |
| EP-2503005-B1 | Cortexolone-17alpha-propionate in hydrate crystalline form IV | CASSIOPEA S P A (IT) | 2015-09-02 | — | — | EP | disclosed |
| US-8785427-B2 | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives | COSMO DERMATOS SRL (IT) | 2014-07-22 | — | — | US | disclosed |
| US-20140179654-A1 | ENZYMATIC PROCESS FOR OBTAINING 17 ALPHA- MONOESTERS OF CORTEXOLONE AND/OR ITS 9,11- DEHYDRODERIVATIVES | COSMO SPA (IT) | 2014-06-26 | — | — | US | disclosed |
| EP-2173891-B1 | Enzymatic process for obtaining cortexolone-17-alpha-propionate in crystalline form III | COSMO DERMATOS SRL (IT) | 2014-02-12 | — | — | EP | disclosed |
| EP-2503005-A2 | Cortexolone-17alpha-propionate in cristalline hydrate form IV | Cosmo S.p.A. (IT) | 2012-09-26 | — | — | EP | disclosed |
| EP-2503004-A1 | Cortexolone-17alpha-propionate in crystalline form I | Cosmo S.p.A. (IT) | 2012-09-26 | — | — | EP | disclosed |
| US-20110092472-A1 | ENZYMATIC PROCESS FOR OBTAINING 17 ALPHA- MONOESTERS OF CORTEXOLONE AND/OR ITS 9,11- DEHYDRODERIVATIVES | COSMO SPA (IT) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200155572-A1 | ENZYMATIC PROCESS FOR OBTAINING 17 ALPHA-MONOESTERS OF CORTEXOLONE AND/OR ITS 9,11-DEHYDRODERIVATIVES | CYP17A1, HSD17B1, HSD11B1 | HSD17B10 21/4885SHBG 219/4885SMN1; SMN2 4878/4885 |
| US-11207332-B2 | Enzymatic process for obtaining 17 α-monoesters of cortexolone and/or its 9,11-dehydroderivatives | CYP17A1, HSD17B1, HSD11B1 | HSD17B10 21/4885SHBG 222/4885SMN1; SMN2 4878/4885 |
| US-11938141-B2 | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives | CYP17A1, HSD17B1, HSD11B1 | HSD17B10 21/4885SHBG 219/4885SMN1; SMN2 4878/4885 |
| US-20160051566-A1 | Enzymatic Process for Obtaining 17 Alpha-Monoesters of Cortexolone and/or Its 9,11-Dehydroderivatives | CYP17A1, HSD17B1, HSD11B1 | HSD17B10 21/4885SHBG 219/4885SMN1; SMN2 4878/4885 |
| US-10159682-B2 | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives | CYP17A1, HSD17B1, HSD11B1 | HSD17B10 21/4885SHBG 219/4885SMN1; SMN2 4878/4885 |
| US-20110092472-A1 | ENZYMATIC PROCESS FOR OBTAINING 17 ALPHA- MONOESTERS OF CORTEXOLONE AND/OR ITS 9,11- DEHYDRODERIVATIVES | CYP17A1, HSD17B1, HSD11B1 | HSD17B10 22/4885SHBG 214/4885SMN1; SMN2 4880/4885 |
| US-10716796-B2 | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives | CYP17A1, HSD17B1, HSD11B1 | HSD17B10 21/4885SHBG 219/4885SMN1; SMN2 4878/4885 |
| US-10166245-B2 | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives | CYP17A1, HSD17B1, HSD11B1 | HSD17B10 21/4885SHBG 219/4885SMN1; SMN2 4878/4885 |
| US-20230104965-A1 | ENZYMATIC PROCESS FOR OBTAINING 17 ALPHA-MONOESTERS OF CORTEXOLONE AND/OR ITS 9,11-DEHYDRODERIVATIVES | CYP17A1, HSD17B1, HSD11B1 | HSD17B10 21/4885SHBG 219/4885SMN1; SMN2 4878/4885 |
| US-20140179654-A1 | ENZYMATIC PROCESS FOR OBTAINING 17 ALPHA- MONOESTERS OF CORTEXOLONE AND/OR ITS 9,11- DEHYDRODERIVATIVES | CYP17A1, HSD17B1, HSD11B1 | HSD17B10 22/4885SHBG 214/4885SMN1; SMN2 4880/4885 |
| US-20190083511-A1 | ENZYMATIC PROCESS FOR OBTAINING 17 ALPHA-MONOESTERS OF CORTEXOLONE AND/OR ITS 9,11-DEHYDRODERIVATIVES | CYP17A1, HSD17B1, HSD11B1 | HSD17B10 21/4885SHBG 219/4885SMN1; SMN2 4878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.